LGALS9 and Patent ductus arteriosus: Similarly, in another PDA mouse model, K-rasLSL.G12D/+;Trp53R172H/+;Pdx-1-Cre (KPC), anti-Gal-9 (RG9-1) treatment caused significant tumor regression and prolonged survival [198].